Simplify Logo

Full-Time

Senior/Principal Scientist

In Vivo Bioanalytics, Gene Therapy Research

Confirmed live in the last 24 hours

Fractyl Health, Inc

Fractyl Health, Inc

51-200 employees

Therapies for Type 2 Diabetes

Biotechnology
Healthcare

Senior, Expert

Burlington, MA, USA

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD in biology, molecular biology, physiology, or relevant research field
  • OR a Master’s degree with 10-12 years relevant industry experience
  • 5-10 years of highly relevant post-PhD experience either in an academic or industry environment
  • Experience planning and managing small and/or large animal studies
  • Experience working with preclinical and bioanalytical CROs
  • Experience in development and optimization of bioanalytical assays relevant to AAV gene therapy pharmacology and safety (e.g. biodistribution, GOI RNA expression and protein quantification, ADA, nAb/Tab, ELISpot)
  • Experience with molecular and cellular biology instruments and techniques, e.g., DNA/RNA/Protein purification, ddPCR and qPCR, flow cytometry, Western blotting, MSD, ELISAs, TapeStation, JESS
  • Experience and/or willingness to work with small and large animal models and tissues
  • Successful track record of working in high-growth and dynamic organizations
  • Demonstrated record of intellectual curiosity, innovation and creative problem solving with an entrepreneurial spirit
  • Ability to lead fast-paced projects with a keen sense of urgency to get the job done well
  • Evidence of "hands-on" experience and expertise
  • Proven and successful track record as a team-player and collaborator in small working environments
  • Highly organized and detail oriented with a passion to deliver quality results
  • Excellent verbal and written communication skills, with experience translating technical concepts into user-friendly documentation
  • Highest levels of professionalism, confidence, personal values and ethical standards
Responsibilities
  • Collaborate cross-functionally and with preclinical CROs to support the planning and execution of in vivo studies
  • Provide scientific/technical diligence and oversight on assay development activities for in vivo study sample analysis measuring gene therapy delivery, pharmacology, safety, and efficacy
  • Coordinate logistics, manage, and monitor timely completion of downstream bioanalytic analyses
  • Consolidate data across different in vivo bioanalytical workstreams toward preparation of study reports
  • Contribute to identification of potential new CRO and academic collaborative partners and assist in GLP audits
  • Develop timelines and milestones to ensure timely completion of deliverables internally and externally
  • Contribute to in vivo discovery and early proof of concept efforts for new projects in Fractyl’s pipeline
  • Prepare technical reports, summaries, protocols, quantitative analysis, and presentations for experimental results
  • Manage, train, and develop junior research scientist/s
  • Bring forward essential bioanalytic assays for assessment of immunotolerability of AAV gene therapy
  • Perform all activities in compliance with applicable regulations, Fractyl’s policies and guidelines, including, but not limited to, timely documentation of activities and maintaining all required applicable training
  • Bring a “can do” spirit to work and deliver on other responsibilities as assigned

Fractyl Health focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy platform aimed at improving the function of pancreatic islet cells, which are essential for blood sugar regulation. By enhancing these cells, Fractyl hopes to achieve long-term remission for patients with T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still awaiting full FDA approval. Unlike many competitors, Fractyl's approach centers on gene therapy to address the underlying issues of these diseases rather than just managing symptoms. The company's goal is to transform the treatment landscape for T2D and obesity, ultimately preventing and eliminating these conditions.

Company Stage

IPO

Total Funding

$395.4M

Headquarters

Lexington, Kentucky

Founded

2010

Growth & Insights
Headcount

6 month growth

11%

1 year growth

18%

2 year growth

28%
Simplify Jobs

Simplify's Take

What believers are saying

  • Fractyl's innovative approach to metabolic diseases could revolutionize treatment paradigms, offering significant career growth opportunities in a pioneering field.
  • The appointment of experienced leaders like Adrian Kimber and Dr. Timothy Kieffer strengthens the company's strategic and scientific capabilities, enhancing its market positioning.
  • Successful IPO and promising preclinical results for Rejuva indicate strong financial backing and potential for substantial market impact.

What critics are saying

  • The success of Fractyl Health is heavily dependent on the regulatory approval and commercial adoption of its therapies, which are still in preclinical or early clinical stages.
  • The competitive landscape for diabetes and obesity treatments is intense, with numerous established players and emerging startups vying for market share.

What makes Fractyl Health, Inc unique

  • Fractyl Health focuses on gene therapy for Type 2 Diabetes and obesity, targeting the root causes of these diseases, unlike many competitors who focus on symptom management.
  • Their flagship product, Rejuva, aims to enhance pancreatic islet cell function, offering a potential long-term remission solution for T2D and obesity.
  • The company has achieved a CE mark for Rejuva, indicating compliance with stringent health and safety standards in the European Economic Area, setting it apart from competitors still in investigational stages.